enzyme: If I had the time, the energy & I was a researcher I would definitely look at this closely.
Since these assertions are being made of COX-2 inhibitors in general, there should be sufficient research already done to substantiate the hypothesis - or even people on this board with relevant celecoxib (Celebrex) or naproxen (Aleve) experience.
It seems that the timing of taking the drug is crucial: for acute episodes, let nature take its course; if it gets chronic though, intervention may be salutary.
http://ajsm.highwire...tract/32/7/1743The American Journal of Sports Medicine 32:1743-1747 (2004)
© 2004 American Orthopaedic Society for Sports Medicine
Parecoxib Impairs Early Tendon Repair but Improves Later Remodeling
Olena Virchenko, MD, Björn Skoglund and Per Aspenberg, MD, PhD*
From the Section for Orthopaedics and Sports Medicine, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linköping, Sweden
Background: Cyclooxygenase-2 inhibitors inhibit bone repair.
Hypothesis: Cyclooxygenase inhibitors might also have a negative effect on early tendon repair, although a positive effect on latme tendon repair previously has been shown.
Study Design: Controlled laboratory study.
Methods: Achilles tendon transection was performed on 80 rats. Sixty rats were given daily intramuscular injections of either parecoxib (6.4 mg/kg body weight) or saline for the first 5 days after surgery and sacrificed either at 8 or 14 days. The remaining 20 rats were given intramuscular parecoxib or saline injections from day 6 until sacrifice at 14 days.
Results: At 8 days, early parecoxib treatment caused a 27% decrease in force at failure (P = .007), a 25% decrease in maximum stress (P = .01), and a 31% decrease in energy uptake (P = .05). Stiffness and transverse area were not significantly affected. At 14 days, early parecoxib treatment caused a decrease in stiffness (P = .004). In contrast to early treatment, late parecoxib treatment caused a 16% decrease in cross-sectional area (P = .03) and a 29% increase in maximum stress (P = .04).
Conclusions: During early tendon repair, a cyclooxygenase-2 inhibitor had a detrimental effect. During remodelling, however, inflammation appears to have a negative influence, and cyclooxygenase-2 inhibitors might be of value.
Clinical Relevance: The results suggest that cyclooxygenase-2 inhibitors should be used with care in the early period after tendon injury.
Here's something more recent:
Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain.
Wang XM, Wu TX, Hamza M, Ramsay ES, Wahl SM, Dionne RA.
NINR/NIH, Bethesda, MD 20892, USA.
New insights into the biological properties of cyclooxygenase-2 (COX-2) and its response pathway challenge the hypothesis that COX-2 is simply pro-inflammatory and inhibition of COX-2 solely prevents the development of inflammation and ameliorates inflammatory pain. The present study performed a comprehensive analysis of gene/protein expression induced by a selective inhibitor of COX-2, rofecoxib, compared with a non-selective COX inhibitor, ibuprofen, and placebo in a clinical model of acute inflammatory pain (the surgical extraction of impacted third molars) using microarray analysis followed by quantitative RT-PCR verification and Western blotting. Inhibition of COX-2 modulated gene expression related to inflammation and pain, the arachidonic acid pathway, apoptosis/angiogenesis, cell adhesion and signal transduction. Compared to placebo, rofecoxib treatment increased the gene expression of ANXA3 (annexin 3), SOD2 (superoxide dismutase 2), SOCS3 (suppressor of cytokine signaling 3) and IL1RN (IL1 receptor antagonist) which are associated with inhibition of phospholipase A(2) and suppression of cytokine signaling cascades, respectively. Both rofecoxib and ibuprofen treatment increased the gene expression of the pro-inflammatory mediators, IL6 and CCL2 (chemokine C-C motif ligand 2), following tissue injury compared to the placebo treatment. These results indicate a complex role for COX-2 in the inflammatory cascade in addition to the well-characterized COX-dependent pathway, as multiple pathways are also involved in rofecoxib-induced anti-inflammatory and analgesic effects at the gene expression level. These findings may also suggest an alternative hypothesis for the adverse effects attributed to selective inhibition of COX-2.
PMID: 17070997
The lesson I take away at this stage of the game is to avoid getting injured (be less strenuously active - after all, this is about extending life, not beating records), so as to be able to continue to take Res. without misgivings.
Read more about inflammation and aging in last week's Discover article:
http://discovermagaz...w...t:int=0&-C= Oh, and I couldn't resist:
My tendons are a pain in the ass. Literally
Both cheeks' tendons? :>